How pharma wants to break the efficacy ceiling in IBD
Despite major shifts in the IBD landscape, most approaches that go beyond targeting inflammation remain in the earlier stages of development.
Despite major shifts in the IBD landscape, most approaches that go beyond targeting inflammation remain in the earlier stages of development.